AI English summary of an SEC filing — figures as filed
Bunge Global BGBunge said full-year GAAP diluted EPS was $7.99 compared with $14.87 in the prior year; on an adjusted basis excluding certain gains and charges and mark-to-market timing differences, it was $9.19 compared with $13.66 in the prior year. Q4 GAAP diluted EPS was $4.36 compared with $4.18 in the prior year; on an adjusted basis it was $2.13 compared with $3.70 in the prior year.
Key points
AI summaryBunge said full-year GAAP diluted EPS was $7.99 compared with $14.87 in the prior year; on an adjusted basis excluding certain gains and charges and mark-to-market timing differences, it was $9.19 compared with $13.66 in the prior year. Q4 GAAP diluted EPS was $4.36 compared with $4.18 in the prior year; on an adjusted basis it was $2.13 compared with $3.70 in the prior year.
The company said full-year Total EBIT was $1,792 million compared with $3,333 million in the prior year, and Adjusted Total EBIT was $2,017 million compared with $3,031 million in the prior year. Full-year Agribusiness Segment EBIT was $1,301 million compared with $2,786 million in the prior year.
Bunge said full-year cash provided by operating activities was $1,900 million compared with $3,308 million in the prior year, citing lower net income and net changes in working capital as factors for the decrease. Full-year share repurchases totaled $1,100 million and dividend payments were $378 million.
The company completed the sale of its 50% interest in BP Bunge Bioenergia on October 1, 2024, with the gain on the sale of $195 million included in Q4 EBIT. It said full-year 2025 adjusted EPS is expected to be approximately $7.75.
Summary
AI-writtenAnalysis scope · Filing body and confirmed press-release exhibitWe analyzed the opening part of the filing body and confirmed exhibits, within a length limit. This is not a review of other exhibits, investor presentations or the full earnings call.
Full-year GAAP diluted EPS $7.99, adjusted basis $9.19
Bunge said full-year GAAP diluted EPS was $7.99 compared with $14.87 in the prior year; on an adjusted basis excluding certain gains and charges and mark-to-market timing differences, it was $9.19 compared with $13.66 in the prior year. Q4 GAAP diluted EPS was $4.36 compared with $4.18 in the prior year; on an adjusted basis it was $2.13 compared with $3.70 in the prior year.
Source · Based on the filing body and exhibits
Full-year Total EBIT $1,792 million, Adjusted Total EBIT $2,017 million
The company said full-year Total EBIT was $1,792 million compared with $3,333 million in the prior year, and Adjusted Total EBIT was $2,017 million compared with $3,031 million in the prior year. Full-year Agribusiness Segment EBIT was $1,301 million compared with $2,786 million in the prior year.
Source · Based on the filing body and exhibits
Full-year cash provided by operating activities $1,900 million, share repurchases $1,100 million
Bunge said full-year cash provided by operating activities was $1,900 million compared with $3,308 million in the prior year, citing lower net income and net changes in working capital as factors for the decrease. Full-year share repurchases totaled $1,100 million and dividend payments were $378 million.
Source · Based on the filing body and exhibits
BP Bunge Bioenergia 50% interest sale and 2025 adjusted EPS outlook
The company completed the sale of its 50% interest in BP Bunge Bioenergia on October 1, 2024, with the gain on the sale of $195 million included in Q4 EBIT. It said full-year 2025 adjusted EPS is expected to be approximately $7.75.
Source · Based on the filing body and exhibits
AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.
Original filing
The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.
Loading the filing text…